Pathological complete response in a patient with pleural mesothelioma treated with immunotherapy: a case report.
immunotherapy
multimodal treatment
pathological complete response
pleural mesothelioma
surgery
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2024
2024
Historique:
received:
29
01
2024
accepted:
26
03
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
epublish
Résumé
The role of immunotherapy in the multimodal treatment for pleural mesothelioma (PM) is still under investigation, particularly in the preoperative setting. Pathological complete response (pCR) has been previously described after chemotherapy and immunotherapy; however, there is no prior experience reported with immunotherapy alone before surgery. We report the case of a 58-year-old male with biphasic PM treated with immunotherapy, resulting in a major clinical partial response. Following a multidisciplinary evaluation between thoracic surgeons, medical oncologists, pathologists, radiologists and radiation oncologists, the patient underwent surgery with radical intent through a right extended pleurectomy/decortication (eP/D). Histopathological examination of the specimen confirmed a pathological Complete Response (pCR). This case supports the feasibility and potential efficacy of combining preoperative immunotherapy with surgery in the management of advanced PM.
Identifiants
pubmed: 38686194
doi: 10.3389/fonc.2024.1378530
pmc: PMC11056523
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1378530Informations de copyright
Copyright © 2024 Faccioli, Grosso, Dell’Amore, Delfanti, Zambello, Cerbone, Canu, De Angelis, Sambataro, Pezzuto, Barbieri, Pasello, Calabrese and Rea.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Références
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Lancet Oncol. 2020 Sep;21(9):1213-1223
pubmed: 32888453
Cancer Treat Rev. 2013 Feb;39(1):10-7
pubmed: 22459200
Clin Cancer Res. 2023 Feb 1;29(3):548-559
pubmed: 36469573
Front Oncol. 2022 Apr 28;12:836751
pubmed: 35574305
Ann Oncol. 2022 Feb;33(2):129-142
pubmed: 34861373
BMJ Open. 2020 Sep 1;10(9):e038892
pubmed: 32873681